Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Teijin Pharma Limited - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Teijin Pharma Limited - Product Pipeline Review - 2015', provides an overview of the Teijin Pharma Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Teijin Pharma Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Teijin Pharma Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Teijin Pharma Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Teijin Pharma Limited's pipeline products Reasons to buy - Evaluate Teijin Pharma Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Teijin Pharma Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Teijin Pharma Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Teijin Pharma Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teijin Pharma Limited - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Teijin Pharma Limited and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Teijin Pharma Limited Snapshot 5 Teijin Pharma Limited Overview 5 Key Information 5 Key Facts 5 Teijin Pharma Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Teijin Pharma Limited - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Teijin Pharma Limited - Pipeline Products Glance 14 Teijin Pharma Limited - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Teijin Pharma Limited - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Teijin Pharma Limited - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Teijin Pharma Limited - Drug Profiles 19 immune globulin (human) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 abaloparatide 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ADC-3680 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 KTP-001 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 lanreotide acetate 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 TMG-123 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Target ROR gamma for Autoimmune Diseases 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Teijin Pharma Limited - Pipeline Analysis 31 Teijin Pharma Limited - Pipeline Products by Target 31 Teijin Pharma Limited - Pipeline Products by Route of Administration 32 Teijin Pharma Limited - Pipeline Products by Molecule Type 33 Teijin Pharma Limited - Pipeline Products by Mechanism of Action 34 Teijin Pharma Limited - Recent Pipeline Updates 35 Teijin Pharma Limited - Dormant Projects 40 Teijin Pharma Limited - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 NTC-801 41 taspoglutide 41 Teijin Pharma Limited - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Teijin Pharma Limited, Key Information 5 Teijin Pharma Limited, Key Facts 5 Teijin Pharma Limited - Pipeline by Indication, 2015 7 Teijin Pharma Limited - Pipeline by Stage of Development, 2015 8 Teijin Pharma Limited - Monotherapy Products in Pipeline, 2015 9 Teijin Pharma Limited - Partnered Products in Pipeline, 2015 10 Teijin Pharma Limited - Partnered Products/ Combination Treatment Modalities, 2015 11 Teijin Pharma Limited - Out-Licensed Products in Pipeline, 2015 12 Teijin Pharma Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015 13 Teijin Pharma Limited - Phase III, 2015 14 Teijin Pharma Limited - Phase II, 2015 15 Teijin Pharma Limited - Phase I, 2015 16 Teijin Pharma Limited - Preclinical, 2015 17 Teijin Pharma Limited - Discovery, 2015 18 Teijin Pharma Limited - Pipeline by Target, 2015 31 Teijin Pharma Limited - Pipeline by Route of Administration, 2015 32 Teijin Pharma Limited - Pipeline by Molecule Type, 2015 33 Teijin Pharma Limited - Pipeline Products by Mechanism of Action, 2015 34 Teijin Pharma Limited - Recent Pipeline Updates, 2015 35 Teijin Pharma Limited - Dormant Developmental Projects,2015 40 Teijin Pharma Limited - Discontinued Pipeline Products, 2015 41 Teijin Pharma Limited, Other Locations 42 Teijin Pharma Limited, Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
